Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SLAMF7 CAR-T
- Development stage
- Phase 2
- Lead developer
- University Hospital Würzburg
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
SLAMF7 CAR-T is an autologous chimeric antigen receptor (CAR)-T cell therapy under development for the treatment of advanced multiple myeloma (MM). This innovative therapy is designed to target the signaling lymphocytic activation molecule F7 (SLAMF7) antigen, which is highly expressed on multiple myeloma cells. The CAR-T cells are manufactured using a virus-free gene-transfer method, specifically the Sleeping Beauty transposon system, and are formulated to contain equal proportions of CD8 cytotoxic and CD4 helper SLAMF7 CAR-T cells. It represents a novel, immune-based approach for patients with MM who have exhausted conventional treatment options.
02
Targets
SLAMF7 (Signaling lymphocytic activation molecule family member 7)
Beyond the preview
Go deeper on SLAMF7 CAR-T.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SLAMF7 CAR-T.